{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:03:27Z","timestamp":1788339807559,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ccl.2007.12.014","type":"journal-article","created":{"date-parts":[[2008,4,12]],"date-time":"2008-04-12T17:19:08Z","timestamp":1208020748000},"page":"251-265","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic and Thrombolytic Therapy for Ischemic Stroke"],"prefix":"10.1016","volume":"26","author":[{"given":"Oriana","family":"Cornett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenore C.","family":"Ocava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samit","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccl.2007.12.014_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/01.STR.29.2.415","article-title":"The Greater Cincinnati\/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks","volume":"29","author":"Broderick","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib2","series-title":"Stroke\/brain attack briefing","author":"National Stroke Association","year":"1996"},{"key":"10.1016\/j.ccl.2007.12.014_bib3","series-title":"Population projections of the US by age, sex, race, and Hispanic origin 1945 to 2050","author":"Day","year":"1996"},{"key":"10.1016\/j.ccl.2007.12.014_bib4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jama.281.12.1112","article-title":"Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association","volume":"281","author":"Gorelick","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib5","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJM199511233332106","article-title":"Primary prevention of stroke","volume":"333","author":"Bronner","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Antiplatelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy\u2014I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.ccl.2007.12.014_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.57.3.326","article-title":"Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses","volume":"57","author":"Hart","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ccl.2007.12.014_bib8","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1161\/01.STR.30.9.1764","article-title":"Prospective study of aspirin use and risk of stroke in women","volume":"30","author":"Iso","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archneur.1986.00520010065026","article-title":"Cardiogenic brain embolism","volume":"43","author":"Cerebral Embolism Task Force","year":"1986","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ccl.2007.12.014_bib11","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/01.CIR.0000017498.88393.44","article-title":"Effect of medical treatment in stroke patients with patent foramen ovale. Patent Foramen Ovale in Stroke Study","volume":"105","author":"Homma","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2007.12.014_bib12","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/01.STR.24.12.1865","article-title":"Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age: a study using transesophageal echocardiography","volume":"24","author":"Cabanes","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial haemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archinte.1996.00440040081009","article-title":"Bleeding during antithrombotic therapy in patients with atrial fibrillation","volume":"156","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.STR.31.4.817","volume":"31","author":"Yamaguchi","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","article-title":"Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation","volume":"141","author":"Fang","year":"2004","journal-title":"Ann Intern Med"},{"issue":"Suppl 4","key":"10.1016\/j.ccl.2007.12.014_bib17","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1212\/WNL.49.5_Suppl_4.S39","article-title":"Risk factors, outcomes, and stroke subtypes for ischemic stroke","volume":"49","author":"Sacco","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ccl.2007.12.014_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cardfail.2005.07.007","article-title":"Warfarin Versus Aspirin in Patients with Reduced Cardiac Ejection Fraction (WARCEF): rationale, objectives, and design","volume":"1","author":"Pullicino","year":"2006","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.ccl.2007.12.014_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cardfail.2004.02.006","article-title":"The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics","volume":"10","author":"Massie","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.ccl.2007.12.014_bib20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","article-title":"The Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. The SALT Collaborative Group","volume":"338","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1016\/j.ccl.2007.12.014_bib21","first-page":"S25","article-title":"Antiplatelet therapy: new foundations for optimal treatment decisions","volume":"53","author":"Albers","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ccl.2007.12.014_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/01.STR.27.4.585","article-title":"Aspirin wars: the optimal dose of aspirin prevent stroke","volume":"27","author":"Hart","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"United Kingdom Transient Ischemic Attack (UK-TIA) Aspirin trial final results","volume":"54","author":"The UK-TIA Study Group","year":"1991","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.ccl.2007.12.014_bib24","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","article-title":"A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack on minor ischemic stroke","volume":"325","author":"The Dutch TIA Trial Study Group","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/ajhp\/56.15.1505","article-title":"Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults","volume":"56","author":"Sachdev","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ccl.2007.12.014_bib26","series-title":"Ticlopidine, platelets and vascular diseases","first-page":"41","article-title":"Ticlopidine's mechanism of action on platelets","author":"Harker","year":"1993"},{"key":"10.1016\/j.ccl.2007.12.014_bib27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2007.12.014_bib28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group","volume":"321","author":"Hass","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.281.9.806","article-title":"Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb\/IIIa inhibitor for stenting","volume":"281","author":"Steinhubl","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1212\/WNL.42.1.111","article-title":"Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup","volume":"42","author":"Grotta","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ccl.2007.12.014_bib31","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.289.22.2947","article-title":"Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial","volume":"289","author":"Gorelick","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2007.12.014_bib33","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","article-title":"Thrombotic thrombocytopenic purpura associated with clopidogrel","volume":"342","author":"Bennett","year":"2000","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.ccl.2007.12.014_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ccl.2007.12.014_bib35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/archneur.56.9.1087","article-title":"Dipyridamole plus aspirin in cerebrovascular disease","volume":"56","author":"Wilterdink","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ccl.2007.12.014_bib36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1742-1241.2001.tb11007.x","article-title":"Cardiac safety in the European Stroke Prevention Study 2 (ESPS2)","volume":"55","author":"Diener","year":"2001","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ccl.2007.12.014_bib37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2007.12.014_bib39","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1161\/01.STR.0000142218.16757.39","article-title":"Major ongoing stroke trials","volume":"35","author":"ESPIRIT Group","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib40","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/01.STR.30.8.1716","article-title":"Therapeutic benefit: aspirin revisited in light of the introduction of clopidogrel","volume":"30","author":"Gorelick","year":"1999","journal-title":"Stroke"},{"issue":"5\u20136","key":"10.1016\/j.ccl.2007.12.014_bib41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000100105","volume":"23","author":"Diener","year":"2007","journal-title":"Cerebrovasc Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2007.12.014_bib42","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/ajhp\/55.suppl_1.S17","article-title":"Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease","volume":"55","author":"Harbison","year":"1998","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ccl.2007.12.014_bib43","series-title":"The pharmacological basis of therapeutics","first-page":"1350","article-title":"Anticoagulant, antithrombotic and thrombolytic drugs","author":"Levine","year":"1975"},{"key":"10.1016\/j.ccl.2007.12.014_bib44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/01.STR.24.8.1251","article-title":"Controversies in stroke: past and present. The Willis Lecture","volume":"24","author":"Dyken","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","article-title":"A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin","volume":"42","author":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ccl.2007.12.014_bib46","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"Mohr","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib47","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jama.291.5.576","article-title":"Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke","volume":"291","author":"Investigators APASS","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib49","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N Engl J Med"},{"issue":"3 Suppl","key":"10.1016\/j.ccl.2007.12.014_bib50","doi-asserted-by":"crossref","first-page":"483S","DOI":"10.1378\/chest.126.3_suppl.483S","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Albers","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ccl.2007.12.014_bib51","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","author":"The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199906103402302","article-title":"Effects\u00a0of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group","volume":"340","author":"Kwiatkowski","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib53","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)","volume":"274","author":"Hacke","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib54","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2007.12.014_bib55","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","article-title":"Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial","volume":"282","author":"Clark","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib56","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jama.283.9.1145","article-title":"Prospective, monitored, multicenter, post-approval experience with intravenous t-PA for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study","volume":"283","author":"Albers","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib57","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJM199710303371812","article-title":"Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis: not a panacea for ischemic stroke","volume":"337","author":"Caplan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib58","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/01.STR.28.5.957","article-title":"Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study","volume":"28","author":"Larrue","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib59","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/01.STR.31.2.370","article-title":"Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience","volume":"31","author":"Tanne","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/01.STR.0000149938.08731.2c","article-title":"The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase","volume":"36","author":"Hacke","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib61","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","article-title":"Intra-arterial\u00a0prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial","volume":"282","author":"Furlan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib62","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.STR.0000121641.77121.98","article-title":"Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study","volume":"35","author":"IMS-Study Investigators","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib63","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group","volume":"349","author":"The International Stroke Trial (IST)","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2007.12.014_bib64","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(97)22022-2","article-title":"Aspirin or heparin immediately after a stroke?","volume":"349","author":"Bousser","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2007.12.014_bib65","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.279.16.1265","article-title":"Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators","volume":"279","author":"The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ccl.2007.12.014_bib66","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archneur.56.9.1098","article-title":"Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment","volume":"56","author":"Chamorro","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ccl.2007.12.014_bib67","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJM199512143332402","article-title":"Low-molecular-weight heparin for the treatment of acute ischemic stroke","volume":"333","author":"Kay","year":"1995","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.ccl.2007.12.014_bib68","first-page":"19","article-title":"Fraxiparine in Ischemic Stroke Study (FISS bis). Presented at the 7th European Stroke Conference 1998. Edinburgh, UK","author":"Hommel","year":"1998","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.ccl.2007.12.014_bib69","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archinte.1996.00440080047006","article-title":"Aging and heparin-related bleeding","volume":"156","author":"Campbell","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccl.2007.12.014_bib70","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group","volume":"349","author":"CAST","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2007.12.014_bib71","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/01.STR.31.6.1240","article-title":"Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups","volume":"31","author":"Chen","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.ccl.2007.12.014_bib72","article-title":"Cooling therapy for acute stroke","volume":"2","author":"Correia","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccl.2007.12.014_bib73","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa052980","article-title":"NXY-057 for acute ischemic stroke","volume":"354","author":"Lees","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ccl.2007.12.014_bib74","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/01.STR.0000171066.25248.1d","article-title":"Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial","volume":"36","author":"Smith","year":"2005","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.ccl.2007.12.014_bib75","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1161\/01.STR.0000260187.33864.a7","article-title":"Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials","volume":"38","author":"Flint","year":"2007","journal-title":"Stroke"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386510700152X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386510700152X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T18:27:08Z","timestamp":1684348028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386510700152X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S073386510700152X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2007.12.014","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}